Project Grant R21CA316981
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $422K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $432,134 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on June 5, 2025, with a completion date of May 31, 2027. This grant funds research into IL13RA2-targeted radioimmunotherapy (RIT) for glioblastoma, an aggressive primary brain tumor with poor prognosis. The research focuses on developing and evaluating therapeutic approaches that...
- The National Cancer Institute awarded Massachusetts General Hospital $652,908 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research restoring dendritic-cell-derived immune signaling to reinvigorate T cells in glioblastoma. The project addresses the failure of immunotherapy to produce durable benefit in glioblastoma multiforme, the most aggressive primary brain tumor in adults, where standard treatments—surgery, radiation, and temozolomide—extend...
- The National Cancer Institute awarded the University of Texas MD Anderson Cancer Center $645,865 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate how perineural invasion in cutaneous squamous cell carcinoma drives immunotherapy resistance through neuroimmune mechanisms. The research addresses the molecular pathway linking nerve invasion to tumor immune suppression. The project will investigate how activating transcription factor 3 (ATF3)-dependent transcriptional...
- The National Institute of Neurological Disorders and Stroke, a division of the Department of Health and Human Services National Institutes of Health, awarded The University of Texas MD Anderson Cancer Center $421,361 on May 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support research targeting RNF2 to synergize with oncolytic immunovirotherapy and induce anti-cancer immunity in medulloblastoma. The research builds on...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $421,685 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center, effective August 1, 2025, through July 31, 2027. This award supports pan-cancer analysis of convergent immunoglobulins from tumor-infiltrating B cells (TIL-B), with the primary deliverable being the identification and characterization of shared B cell receptors (BCR) and antibodies across...
- The National Institutes of Health National Cancer Institute awarded the University of California, Los Angeles $404,972 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to decode mechanisms behind durable immunotherapy responses in glioblastoma. The research uses spatial transcriptomics, high-plex immunofluorescence, and single-cell sequencing to map immune architecture in tumor samples from long-term survivors treated with autologous tumor lysate-pulsed dendritic cell...
- The University of Texas MD Anderson Cancer Center received a $460,940 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 1, 2025, through May 31, 2027. This award supports investigator-initiated research examining how glioma-associated germline risk alleles (single nucleotide polymorphisms or SNPs) impact neurodevelopmental...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $421,685 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and evaluate ultrasound-activated nanodroplet technology (ULTRON) for cancer immunotherapy delivery. The recipient will engineer targeted ultrasound-activatable nanodroplets loaded with cyclic dinucleotides to address barriers in macrophage phagocytosis of cancer cells, tumor-cell antigen...